Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.BTX · Entity 6045 | Vice President & Secretary | December 31, 2016 | February 15, 2017 |
| Serina Therapeutics, Inc.AGE · Entity 9581 | Director of Admin & Secretary | June 04, 2021 | June 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date December 31, 2016 · Filed February 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par valueSEC Table I · non-derivative | Direct | 591,245 |
Reported balance
After 2016-04-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-04-06 · Gift · Disposed 1,900 · Balance 591,245 F1: On April 6, 2016, Ms. Segall gifted 1,900 common shares to a charitable organization. F2: Does not include shares that may be acquired upon the exercise of certain stock options. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2026-01-19 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2016-12-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 25,000 F3: One quarter of the options shall vest on January 19, 2017 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $4.23 · Expires 2025-03-02 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2016-12-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 50,000 F4: One quarter of the options vested on March 2, 2016 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2021-03-19 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2016-12-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 50,000 F5: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 20, 2014. |
| Option to Purchase Common SharesSEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2020-02-19 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2016-12-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 50,000 F6: 1/48th of the number of options vested and became exercisable at the end of each full month of employment after January 1, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2016, Ms. Segall gifted 1,900 common shares to a charitable organization.
F2: Does not include shares that may be acquired upon the exercise of certain stock options.
F3: One quarter of the options shall vest on January 19, 2017 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
F4: One quarter of the options vested on March 2, 2016 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
F5: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 20, 2014.
F6: 1/48th of the number of options vested and became exercisable at the end of each full month of employment after January 1, 2013.
Serina Therapeutics, Inc.
Report date June 04, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Coomon StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2031-06-03 | Direct | 3,000 |
Reported balance
After 2021-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-04 · Grant · Acquired 3,000 · Balance 3,000 F1: Twenty-five percent of the options will vest and thereby become exercisable upon completion of one year of service from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, subject to her continued service as an employee on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent of the options will vest and thereby become exercisable upon completion of one year of service from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, subject to her continued service as an employee on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2021 Filed Jun 8, 2021 21:41 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Coomon Stock · Derivative | 3,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-21-039078 · doc4.xml · derivative · entry 1 SEGALL JUDITH · CIK 0001054745 · Director of Admin & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: Twenty-five percent of the options will vest and thereby become exercisable upon completion of one year of service from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, subject to her continued service as an employee on the applicable vesting date. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Coomon Stock · Derivative | 15,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-19-057696 · doc4.xml · derivative · entry 2 SEGALL JUDITH · CIK 0001054745 · Director, Admin & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-11-18 F1 · derivative.exercise_date: One third shall vest on November 19, 2020 and the remaining shall vest in 24 equal monthly installments thereafter, based upon continuous service. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:07 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Coomon Stock · Derivative | 15,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-19-057696 · doc4.xml · derivative · entry 1 SEGALL JUDITH · CIK 0001054745 · Director, Admin & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-11-18 Read SEC document |
| April 06, 2016 Filed Feb 15, 2017 00:49 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GiftCommon Shares, no par value | 1,900 | $3.25 | $6,175.00 |
DisclosureSEC source: 0001209191-17-010870 · doc5.xml · nonDerivative · entry 1 SEGALL JUDITH · CIK 0001054745 · Vice President & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,245 F1 · shares: On April 6, 2016, Ms. Segall gifted 1,900 common shares to a charitable organization. F2 · balance_after: Does not include shares that may be acquired upon the exercise of certain stock options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.